IP Library › Patent Application 11606650
Patent Application
App. No. 11/606,650

Compositions and methods for detection of a target nucleic acid sequence

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/606,650
Abstract

The present invention is directed compositions having a Fen nuclease consisting of a 5′ to 3′ exonuclease and/or endonuclease activity and pyrophosphate.

Claims (15)

1 . A composition comprising an isolated Fen nuclease consisting of a 5′ to 3′ exonuclease and/or endonuclease activity and a pyrophosphate.

2 . The composition of claim 1 or 2 , further comprising a labeled oligonucleotide.

3 . The composition of claim 1 or 2 , further comprising a nucleic acid primer.

4 . The composition of claim 3 , further comprising a nucleic acid primer.

5 . The composition of claim 1 or 2 , wherein said fen nuclease is thermostable.

6 . The composition of claim 3 , wherein said fen nuclease is thermostable.

7 . The composition of claim 4 , wherein said fen nuclease is thermostable.

8 . The composition of claim 8 , wherein said fen nuclease is selected from the group consisting of a fen nuclease enzyme of Archaeglobus fulgidus, Methanococcus jannaschii, Pyrococcus furiosus , and Pyrococcus horikoshii.

9 . The composition of claim 1 or 2 , further comprising a nucleic acid polymerase that substantially lacks 5′ to 3′ exonuclease activity.

10 . The composition of claim 10 , wherein said nucleic acid polymerase is thermostable.

11 . The composition of claim 11 , wherein said nucleic acid polymerase is selected from the group consisting of Pfu, Pfu-exo, Taq, Yaq-exo, Deep vent and Deep vent exo.

12 . The composition of claim 3 , wherein said nucleic acid primer is between about 10 to 100 nucleotides in length.

13 . The composition of claim 3 , wherein said nucleic acid primer is between about 17-50 nucleotides in length.

14 . The composition of claim 3 , wherein said nucleic acid primer is between about 17-45 nucleotides in length.

15 . The composition of claim 1 , wherein said Fen nuclease is a Fen-1 nuclease.

Assignments (3)
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
EIGHTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Mar 26, 2009
From: CYTYC CORPORATION; HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERSL.P.
Reel/Frame 022456/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: STRATAGENE CALIFORNIA
To: HOLOGIC INC.
Reel/Frame 021976/0268 →